BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations
In This Article:
BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.